- Home
- BRT vs ATYR Comparison
BRT vs ATYR Comparison
Compare BRT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | ATYR |
|---|---|---|
| Founded | 1972 | 2005 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.3M | 83.3M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | BRT | ATYR |
|---|---|---|
| Price | $14.04 | $0.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 8 |
| Target Price | ★ $19.75 | $4.20 |
| AVG Volume (30 Days) | 39.3K | ★ 1.1M |
| Earning Date | 03-13-2026 | 03-05-2026 |
| Dividend Yield | ★ 7.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $2.86 | N/A |
| Revenue Next Year | $6.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.49 | $0.64 |
| 52 Week High | $18.27 | $7.29 |
Technical Indicators
Market Signals| Indicator | BRT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 40.51 |
| Support Level | N/A | $0.67 |
| Resistance Level | $15.11 | $0.85 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 31.51 | 5.89 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).